BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  J&J Taps the Brakes on COVID-19 Vaccine Trial After “Unexplained Illness”

  J&J did not disclose much information about the unexplained illness, stating, “We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”

  October 13, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  In Tough Market, Inventiva’s NASH Drug Receives Breakthrough Therapy Tag

  NASH is a metabolic disease similar to cirrhosis of the liver, but occurs in people who drink little, if any, alcoholic.

  October 13, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  Deals

  Mallinckrodt Files for Chapter 11 Amid Growing Legal Battles in Opioid Crisis

  Mallinckrodt has filed for Chapter 11 bankruptcy amid growing lawsuits that allege the company has participated in fueling the opioid epidemic in the United States.

  October 13, 2020

   · 

  2 min read

   · 

  Brandon May
• 

  Drug Development

  Glitches in the COVID-19 Race: Less than 24 Hours After J&J Pauses Vaccine Trial, Eli Lilly Pauses Antibody Combo Trial

  Eli Lilly announced that it is pausing its clinical trial of a combination antibody against COVID-19 over safety concerns. Typically, this would be because a patient or volunteer showed a serious side effect or became sick, but the company did not clarify what the reason for the pause is.

  October 13, 2020

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Gossamer Bio’s GB001 Shows Minimal Impact in Asthma and Chronic Rhinosinusitis

  Gossamer Bio announced today that its two studies examining GB001 – the Phase IIb LEDA trial in eosinophilic asthma and Phase II TITAN trial in chronic rhinosinusitis – failed to meet their primary endpoints.

  October 13, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  Drug Development

  Dupixent Posts Positive Results in Phase III Pediatric Asthma Study

  In a Phase III study, the biologic (Dupixent) met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.

  October 13, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Exploding Biopharma Industry Going the Distance for Specialized Talent

  The urgency of 2020 has shone a spotlight on the investment and advances in the U.S. biotech industry over the past decade – and overall, it is looking strong.

  October 13, 2020

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Policy

  Voyager Takes a Hit After FDA Places Hold on Gene Therapy for Huntington’s Disease

  The FDA placed the hold onto the program hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters, Voyager said.

  October 13, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Biopharma Update on the Novel Coronavirus: October 13

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.

  October 13, 2020

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  Femtech Trailblazers Talk Innovation and Capitalization to Meet Women’s Underserved Needs

  Femtech represents significant growth opportunities for biotech companies, but is still under the radar for most investors. None-the-less, pioneering companies are emerging to address this sector’s many underserved needs.

  October 13, 2020

   · 

  5 min read

   · 

  Gail Dutton